HIGHLIGHTS
- who: April et al. from the Center for Genetic Engineering and University Verona, Italy have published the article: Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution, in the Journal: (JOURNAL)
- what: The aim of this study was to compare the number of COVID19 patients who progressed to severe disease (defined as grade 5 or more of the OSCI) in the control vs the experimental arm. The authors aimed to study the evolution of cytokines in plasma along treatment, define a cytokine signature in plasma predictive of COVID . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.